Search research articles
Contact Us
Filters
Showing results (91-100 of 122) with videos related to
Page
of 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
M E Gore, J Bellmunt, T Eisen, et al.
British Journal of Cancer
|
March 18, 2010
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
C Montagut, M Iglesias, M Arumi, et al.
Anticancer Research
|
May 15, 1998
p53 oncoprotein as a prognostic indicator in patients with breast cancer
R Molina, M A Segui, M A Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Archivos Espanoles De Urologia
|
June 1, 1996
[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]
J Bellmunt Molins, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2011
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
M D Michaelson, J Bellmunt, G R Hudes, et al.
Cancer Metastasis Reviews
|
August 1, 2015
New advances in genitourinary cancer: evidence gathered in 2014
C Suárez, J Puente, E Gallardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
M De Santis, P J Wiechno, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 122) with videos related to
Sort By:
Page
of 13
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
M E Gore, J Bellmunt, T Eisen, et al.
British Journal of Cancer
|
March 18, 2010
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
C Montagut, M Iglesias, M Arumi, et al.
Anticancer Research
|
May 15, 1998
p53 oncoprotein as a prognostic indicator in patients with breast cancer
R Molina, M A Segui, M A Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Archivos Espanoles De Urologia
|
June 1, 1996
[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]
J Bellmunt Molins, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2011
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
M D Michaelson, J Bellmunt, G R Hudes, et al.
Cancer Metastasis Reviews
|
August 1, 2015
New advances in genitourinary cancer: evidence gathered in 2014
C Suárez, J Puente, E Gallardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
M De Santis, P J Wiechno, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Page
of 13